Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
In clinical trials of Tirzepatide, a dual-acting GLP-1 and GIP agonist currently prescribed for Type 2 diabetes, obese patients lost 21 percent body mass in 1.4 years, surpassing the 15 percent reduction seen with Semaglutide
B.ThompsonP
Until relatively recently, scientists viewed obesity as a single disease, but now experts around the world have begun to realise that it is far more complex
,aspect=ignore)
Similar content being viewed by others Subjects Introduction Lung cancer remains the leading cause of cancer death 1
Chen J, Chu H, Xiong H, Yu Y, Huang X, Zhou L, Chen Q, Bing D, Liu Y, Wang S, Cui Y
US$ 29.92
US$ 25.62
US$ 28.59
US$ 23.80
US$ 20.23
US$ 20.56
US$ 21.13
US$ 28.62
